An experimental vaccine meant to combat peanut allergy came up short on Friday in a large clinical trial, but the company developing it blames the failure on a surprising placebo effect — and believes it still might win Food and Drug Administration approval.
The treatment, called Viaskin Peanut, is a patch designed to gradually train a patient’s immune system to tolerate peanuts. In a trial on more than 300 children with peanut allergies, about 35 percent of patients responded to Viaskin, but the overall results didn’t beat placebo by enough to meet the study’s primary goal.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
About the Author
